Stock RPRX ROYALTY PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
27.33 USD +0.59% Intraday chart for Royalty Pharma plc -3.12% -2.71%
May. 22 Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline MT
May. 16 Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
MT
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
GL
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
AQ
Royalty Pharma : RBC Healthcare Conference Transcript
PU
Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Royalty Pharma : Q1 2024 Financial Results Call Transcript
PU
Transcript : Royalty Pharma plc Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
Royalty Pharma to Present at Upcoming Investor Conferences
GL
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
MT
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash
MT
Royalty Pharma's Q1 Net Income, Revenue Falls
MT
Transcript : Royalty Pharma plc, Q1 2024 Earnings Call, May 09, 2024
Royalty Pharma : Q1 2024 Press Release
PU
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, vs. Street Est of $709.5M
MT
Royalty Pharma: Q1 Earnings Snapshot
AQ
Royalty Pharma Reports First Quarter 2024 Results
GL
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
GL
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
MT
Royalty Pharma : U.K. Companies Act Annual Report - 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPRX Stock
  4. News Royalty Pharma plc